THE UNITED LABORATORIES INTERNATIONAL HOLDINGS LIMITED Financials The United Laboratories International Holdings Limited
Equities
3933
KYG8813K1085
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.72 HKD | +0.69% |
|
-4.39% | +24.39% |
| 06-06 | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
| 06-06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,314 | 10,122 | 7,977 | 8,903 | 12,737 | 15,844 | - | - |
| Enterprise Value (EV) 1 | 11,316 | 9,191 | 6,144 | 6,293 | 9,744 | 9,344 | 8,040 | 5,023 |
| P/E ratio | 13.3 x | 11.7 x | 6.61 x | 4.94 x | 4.35 x | 5.31 x | 5.34 x | 5.13 x |
| Yield | 1.35% | 1.72% | 3.38% | 4.42% | 6.18% | 4.09% | 4.28% | 2.3% |
| Capitalization / Revenue | 1.02 x | 0.98 x | 0.67 x | 0.69 x | 0.86 x | 0.99 x | 0.94 x | 0.9 x |
| EV / Revenue | 1.23 x | 0.89 x | 0.52 x | 0.49 x | 0.65 x | 0.58 x | 0.48 x | 0.29 x |
| EV / EBITDA | 5.76 x | 4.63 x | 2.66 x | 2.09 x | 2.26 x | 2.19 x | 1.88 x | 1.15 x |
| EV / FCF | 8,007,682 x | 7,437,185 x | 4,944,935 x | 4,437,388 x | - | - | - | - |
| FCF Yield | 0% | 0% | 0% | 0% | - | - | - | - |
| Price to Book | 1.28 x | 0.95 x | 0.7 x | 0.74 x | - | 0.97 x | 0.84 x | 0.72 x |
| Nbr of stocks (in thousands) | 1,639,721 | 1,840,391 | 1,829,491 | 1,817,027 | 1,817,027 | 1,817,027 | - | - |
| Reference price 2 | 5.680 | 5.500 | 4.360 | 4.900 | 7.010 | 8.720 | 8.720 | 8.720 |
| Announcement Date | 3/30/20 | 3/30/21 | 3/23/22 | 3/21/23 | 3/27/24 | - | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,167 | 10,378 | 11,915 | 12,930 | 14,892 | 16,052 | 16,816 | 17,557 |
| EBITDA 1 | 1,964 | 1,985 | 2,313 | 3,013 | 4,310 | 4,270 | 4,285 | 4,359 |
| EBIT 1 | 1,244 | 1,691 | 1,891 | 2,180 | 3,465 | 3,531 | 3,501 | 3,632 |
| Operating Margin | 13.57% | 16.3% | 15.87% | 16.86% | 23.26% | 22% | 20.82% | 20.69% |
| Earnings before Tax (EBT) 1 | 919.3 | 1,044 | 1,477 | 2,289 | 3,625 | 3,677 | 3,659 | 3,799 |
| Net income 1 | 701 | 831.6 | 1,213 | 1,804 | 2,928 | 2,982 | 2,975 | 3,092 |
| Net margin | 7.65% | 8.01% | 10.18% | 13.95% | 19.66% | 18.58% | 17.69% | 17.61% |
| EPS 2 | 0.4275 | 0.4710 | 0.6594 | 0.9912 | 1.611 | 1.641 | 1.634 | 1.700 |
| Free Cash Flow | 1,413 | 1,236 | 1,242 | 1,418 | - | - | - | - |
| FCF margin | 15.42% | 11.91% | 10.43% | 10.97% | - | - | - | - |
| FCF Conversion (EBITDA) | 71.95% | 62.25% | 53.71% | 47.08% | - | - | - | - |
| FCF Conversion (Net income) | 201.59% | 148.6% | 102.4% | 78.63% | - | - | - | - |
| Dividend per Share 2 | 0.0765 | 0.0946 | 0.1474 | 0.2168 | 0.4330 | 0.3570 | 0.3735 | 0.2005 |
| Announcement Date | 3/30/20 | 3/30/21 | 3/23/22 | 3/21/23 | 3/27/24 | - | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,700 | 4,826 | 5,286 | 5,669 | 6,120 | 5,950 | 7,018 | 7,442 | 7,407 | 7,186 | 7,452 | 7,185 | 7,457 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | 954.2 | 824.6 | 906.5 | 1,279 | 1,693 | 1,761 | 1,577 | 1,545 | 1,425 | 1,154 |
| Operating Margin | - | - | - | 16.83% | 13.47% | 15.24% | 18.23% | 22.75% | 23.78% | 21.94% | 20.73% | 19.83% | 15.48% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 0.2304 | 0.1342 | 0.3294 | 0.4068 | 0.2436 | 0.3967 | 0.5971 | 0.7617 | 0.8452 | 0.7250 | 0.7140 | 0.6920 | 0.5300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 8/25/20 | 3/30/21 | 8/26/21 | 3/23/22 | 8/23/22 | 3/21/23 | 8/29/23 | 3/27/24 | - | - | - | - |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 2,003 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 931 | 1,833 | 2,610 | 2,993 | 6,501 | 7,805 | 10,821 |
| Leverage (Debt/EBITDA) | 1.02 x | - | - | - | - | - | - | - |
| Free Cash Flow | 1,413 | 1,236 | 1,242 | 1,418 | - | - | - | - |
| ROE (net income / shareholders' equity) | 10% | 9.2% | 11% | 15.9% | 23.1% | 20.7% | 19.1% | 18.2% |
| ROA (Net income/ Total Assets) | 4.24% | 4.59% | 6.31% | 8.96% | 13.5% | 13% | 12.6% | 12.8% |
| Assets 1 | 16,549 | 18,138 | 19,214 | 20,141 | 21,676 | 23,003 | 23,538 | 24,233 |
| Book Value Per Share 2 | 4.440 | 5.770 | 6.230 | 6.650 | - | 8.960 | 10.40 | 12.10 |
| Cash Flow per Share 2 | 1.150 | 1.060 | 0.9900 | 1.270 | - | 1.660 | 1.870 | - |
| Capex 1 | 471 | 637 | 571 | 884 | - | 1,103 | 1,106 | 1,044 |
| Capex / Sales | 5.13% | 6.13% | 4.79% | 6.84% | - | 6.87% | 6.58% | 5.95% |
| Announcement Date | 3/30/20 | 3/30/21 | 3/23/22 | 3/21/23 | 3/27/24 | - | - | - |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.72
HKD
Average target price
12.28
HKD
Spread / Average Target
+40.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.39% | 2.03B | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
- Stock Market
- Equities
- 3933 Stock
- Financials The United Laboratories International Holdings Limited
